WASHINGTON, D.C., March 19, 2013―The Association for the Accreditation of Human Research Protection Programs Inc. has awarded accreditation to Pfizer Inc., strengthening research protections for hundreds of thousands of participants around the globe.
Pfizer is one of three organizations whose accreditation was approved by the AAHRPP Council on Accreditation in March. Others include a healthcare network in Connecticut and an independent institutional review board in Maryland.
The newly accredited organizations are :
- Hartford HealthCare, Hartford Conn.
- MaGil IRB Inc., Rockville, Md.
- Pfizer Inc., New York, N.Y.
The accreditation of Pfizer—the world’s largest research-based pharmaceutical company and the first major commercial research sponsor to attain AAHRPP accreditation— is expected to have global repercussions.
In 2009, Pfizer became the first pharmaceutical company to earn AAHRPP accreditation for its three phase 1 clinical research units, in New Haven, Conn.; Brussels, Belgium; and Singapore. The current accreditation applies to all of Pfizer’s phase 2 through 4 clinical trials.
“AAHRPP accreditation affirms that Pfizer provides a higher level of protection for research participants regardless of where they live or the type of trial involved,” said Marjorie A. Speers, Ph.D., AAHRPP president and CEO.
“Thousands of Pfizer researchers worldwide are conducting research in accordance with the ‘gold standard’ for quality and ethics,” Speers added. “That raises the bar and sets an example for other sponsors to follow.”
AAHRPP accreditation is available to U.S. and international organizations that conduct biomedical, behavioral or social sciences research involving human participants. To date, AAHRPP has accredited organizations in 46 states, Canada, China, India, Korea, Singapore and Taiwan.
About the Association for the Accreditation of Human Research Protection Programs, Inc.
A nonprofit organization, AAHRPP provides accreditation for organizations that conduct human research and can demonstrate that their protections exceed the safeguards required by the U.S. government. To learn more, visit www.aahrpp.org.
For Information Contact:
Sarah H. Kiskaddon
Director of Business Development, Communications and Public Relations